Clinical Trials Sponsored by PharmaBio Development Inc.

Total 1146 results

Eisai Inc.
PharmaBio Development Inc.

Terminated

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Ovarian Cancer

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Belgium, Italy, Spain, United States, Ukraine, United Kingdom
Eisai Inc.
PharmaBio Development Inc.

Terminated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Bladder Cancer

United Kingdom, Netherlands, Spain, Germany, United States, Ukraine
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

United States, Korea, Republic of, Ukraine, United Kingdom
Eisai Inc.
PharmaBio Development Inc.

Terminated

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Rectal Cancer | Colon Cancer

Argentina, Russian Federation, United States, Australia, Brazil, Ukraine
SCRI Development Innovations, LLC
Genentech, Inc.; Pharmacia and Upjohn

Completed

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer

Lung Cancer
Planexta, Inc
Pharmaxi LLC

Completed

Measuring Accuracy of Wristband for Registration of ECG RR-Intervals for One Hand, SenceBand in Comparison to Holter

HRV

Ukraine
Korea University Guro Hospital
Pharmbio Korea Inc.

Not yet recruiting

Intravenous Iron Infusion on Chemotherapy-induced Anemia

Colon Cancer | Chemotherapeutic-Induced Anemia
SCRI Development Innovations, LLC
Novartis; Pharmacia and Upjohn

Completed

Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Lung Cancer
McMaster University
Pharmaxis; AllerGen NCE Inc.

Completed

Mannitol-Induced Cough Challenge in Healthy Controls and Subjects With Mild Allergic Asthma (MICC)

Cough | Asthma

Canada
SCRI Development Innovations, LLC
Aventis Pharmaceuticals; Pharmacia and Upjohn

Terminated

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

Breast Cancer
Duke University
Pharmacia; Keryx / AOI Pharmaceuticals, Inc.

Completed

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

Glioblastoma | Gliosarcoma

United States
Children's Mercy Hospital Kansas City
Leadiant Biosciences, Inc.; Minimed Pharmaceuticals; Pharmacia/Upjohn Career...

Completed

Carnitine Levels and Carnitine Supplementation in Type I Diabetes

Hypoglycemia | Diabetes Mellitus, Type I

United States
Xilio Development, Inc.

Recruiting

XTX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Xilio Development, Inc.

Active, not recruiting

XTX202 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
SCRI Development Innovations, LLC
Eli Lilly and Company; AstraZeneca; Pharmacia and Upjohn

Completed

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

Neoplasms, Unknown Primary

United States
SCRI Development Innovations, LLC
Eli Lilly and Company; Aventis Pharmaceuticals; Pharmacia and Upjohn

Completed

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Breast Cancer
Sunovion Respiratory Development Inc.

Completed

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (GOLDEN7)

COPD

United Kingdom
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Education Development Center, Inc.

Completed

Reducing HIV Risks in African American Teens

HIV Infections

United States
Centocor Research & Development, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (PHOENIX1)

Psoriasis

United States, Belgium, Canada
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Sunovion Respiratory Development Inc.

Completed

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)

COPD

United States
Sunovion Respiratory Development Inc.

Completed

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) (GOLDEN-4)

Chronic Obstructive Pulmonary Disease | COPD

United States
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
C.T. Development America, Inc.

Completed

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

Amyloidosis

Spain, United States, Italy, Belgium, Netherlands, India, Tunisia, Latvia, Turkey, France, Germany, Estonia, Lithuania, Poland, Russian Federation, Georgia, United Kingdom, Israel, Egypt, Finland, Peru, Sweden, Ukraine
C.T. Development America, Inc.

Completed

A Study of RX-10045 in the Treatment of Dry Eye Disease

Dry Eye Syndrome

United States
C.T. Development America, Inc.

Completed

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Education Development Center, Inc.

Completed

Parent Education for Young Teen Females

Prevention

United States
Labcorp Drug Development Inc

Recruiting

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine (PREFER)

Melanoma | Soft Tissue Sarcoma | Stomach Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Rhabdomyosarcoma | Uterine Cancer

United States
Sunovion Respiratory Development Inc.

Completed

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease (COPD)

United States
Sunovion Respiratory Development Inc.

Completed

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-3)

COPD

United States
Sunovion Respiratory Development Inc.

Completed

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-5)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Czechia, Hungary, Russian Federation
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Belgium, Russian Federation
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Education Development Center, Inc.

Unknown

Addressing Proven Factors in HIV Prevention for Latino Youth

HIV | Sexually Transmitted Infections
Aurinia Pharmaceuticals Inc.
Labcorp Drug Development Inc

Recruiting

Voclosporin in Adolescents With Lupus Nephritis (VOCAL)

Adolescent Lupus Nephritis

United States
Otsuka Pharmaceutical Development & Commercialization...
Quintiles, Inc.

Completed

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia (EQUATOR)

Acute Schizophrenia

United States, Malaysia, Serbia, Ukraine, Romania, Puerto Rico, Colombia, Turkey
Alimentiv Inc.
Takeda Development Center Americas, Inc.

Recruiting

Determination of the Optimal Treatment Target in Ulcerative Colitis (VERDICT)

Colitis, Ulcerative

Canada, United Kingdom, Poland, Italy, United States, Belgium, France, Netherlands, Belarus, Ukraine
Bo-In Lee
Pharmbio Korea Co., Ltd.

Completed

Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid

Cathartic Colon

Korea, Republic of
Ironshore Pharmaceuticals and Development, Inc

Not yet recruiting

Ph3 Multicenter, 3wk RDBPC Efficacy, Safety & PK Study of Evening Dosed MPH HCl ER Capsules (HLD200) in Children 4-5 Yr With ADHD

Attention Deficit Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Active, not recruiting

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy

United States
COUR Pharmaceutical Development Company, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

Neurobehavioral Disinhibition

United States

3

Subscribe